LIPI Stock Overview
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lipidor AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.24 |
| 52 Week High | kr2.30 |
| 52 Week Low | kr0.18 |
| Beta | 0.34 |
| 1 Month Change | -56.41% |
| 3 Month Change | -50.51% |
| 1 Year Change | -56.25% |
| 3 Year Change | -98.16% |
| 5 Year Change | n/a |
| Change since IPO | -96.37% |
Recent News & Updates
Recent updates
We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely
Sep 04
Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business
Feb 24We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth
Sep 15Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation
May 13Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth
Jan 29Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares
Dec 07
Shareholder Returns
| LIPI | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 6.5% | 3.1% | 0.6% |
| 1Y | -56.3% | 51.6% | 11.1% |
Return vs Industry: LIPI underperformed the Swedish Pharmaceuticals industry which returned 54.9% over the past year.
Return vs Market: LIPI underperformed the Swedish Market which returned 11.2% over the past year.
Price Volatility
| LIPI volatility | |
|---|---|
| LIPI Average Weekly Movement | 52.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.6% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: LIPI's share price has been volatile over the past 3 months.
Volatility Over Time: LIPI's weekly volatility has increased from 29% to 52% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 8 | Ola Holmlund | lipidor.se |
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.
Lipidor AB (publ) Fundamentals Summary
| LIPI fundamental statistics | |
|---|---|
| Market cap | kr7.10m |
| Earnings (TTM) | -kr11.48m |
| Revenue (TTM) | kr87.00k |
81.6x
P/S Ratio-0.6x
P/E RatioIs LIPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPI income statement (TTM) | |
|---|---|
| Revenue | kr87.00k |
| Cost of Revenue | kr6.53m |
| Gross Profit | -kr6.44m |
| Other Expenses | kr5.05m |
| Earnings | -kr11.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -7,402.30% |
| Net Profit Margin | -13,201.15% |
| Debt/Equity Ratio | -5.6% |
How did LIPI perform over the long term?
See historical performance and comparison